<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 12.1: PCOS and Cardiovascular Health: Beyond the Lipid Panel | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: #f9fafb;
 border-radius: 16px;
 padding: 24px;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
 gap: 12px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #fdf2f4 0%, #f8e7ea 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #722F37;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #1f2937;
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #722F37;
 font-weight: 700;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 color: white;
}

.case-study-content {
 padding: 28px;
}

/* DATA TABLE */
.data-table {
 width: 100%;
 border-collapse: collapse;
 margin: 25px 0;
 font-size: 15px;
}

.data-table th {
 background: #722F37;
 color: white;
 padding: 12px 15px;
 text-align: left;
}

.data-table td {
 padding: 12px 15px;
 border-bottom: 1px solid #e5e7eb;
}

.data-table tr:nth-child(even) {
 background: #f9fafb;
}

/* COACH TIP */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* INTERACTIVE COMPONENTS */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES */
.references-box {
 background: #f8fafc;
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box ol {
 padding-left: 20px;
}

.references-box li {
 font-size: 14px;
 color: #475569;
 margin-bottom: 8px;
}

.module-connection {
 background: #f0f9ff;
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.stat-highlight {
 font-weight: 800;
 color: #722F37;
}

 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 12: Complex Co-morbidities & Life-Stage Management</span>
 <h1 class="lesson-title">PCOS and Cardiovascular Health: Beyond the Lipid Panel</h1>
 <div class="lesson-meta">
 <span class="meta-badge">‚è±Ô∏è 15 min read</span>
 <span class="meta-badge">üí° Lesson 1 of 8</span>
 <span class="meta-badge">üéì Level 1 Deep Dive</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Credential</div>
 <div class="title">AccrediPro Standards Institute‚Ñ¢ Certified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <span class="toc-label">In This Lesson</span>
 <ul class="toc-list">
 <li><a href="#atherogenic-profile"><span class="section-num">01</span>The Atherogenic Lipoprotein Profile</a></li>
 <li><a href="#insulin-axis"><span class="section-num">02</span>The Insulin-Endothelium Axis</a></li>
 <li><a href="#advanced-markers"><span class="section-num">03</span>Beyond LDL: Advanced Biomarkers</a></li>
 <li><a href="#screening-protocols"><span class="section-num">04</span>Long-term Screening Protocols</a></li>
 <li><a href="#interventions"><span class="section-num">05</span>Cardioprotective Interventions</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-text">
 <p><strong>Module Connection:</strong> While earlier modules focused on the mechanics of the S.T.E.A.D.Y. Method‚Ñ¢, Module 12 explores how these foundational shifts prevent the <span class="highlight">long-term metabolic consequences</span> of PCOS, specifically the elevated cardiovascular risk that often accelerates during the perimenopausal transition.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Expert Perspective</h3>
 <p>For decades, cardiovascular risk in PCOS was assessed solely through the lens of the "standard lipid panel." However, emerging research indicates that women with PCOS often possess a <span class="highlight">normal LDL-C</span> while harboring significant subclinical atherosclerosis. As a specialist, your role is to look beneath the surface of "normal" labs to identify the specific lipoprotein patterns and inflammatory markers that drive vascular aging.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Analyze the "Atherogenic Lipoprotein Profile" and why traditional LDL-C measures often underestimate risk in PCOS.</li>
 <li>Explain the physiological mechanism by which hyperinsulinemia induces endothelial dysfunction and arterial stiffness.</li>
 <li>Identify the clinical significance of advanced markers including ApoB, Lp(a), and hs-CRP.</li>
 <li>Implement evidence-based screening protocols, including blood pressure monitoring and CIMT considerations.</li>
 <li>Design targeted nutritional and lifestyle strategies to improve cardiovascular risk scores.</li>
 </ul>
 </div>

 <!-- Case Study -->
 <div class="case-study">
 <div class="case-study-header">
 <p><strong>Clinical Case Study:</strong> Elena, Age 48</p>
 </div>
 <div class="case-study-content">
 <p><strong>Profile:</strong> Elena is a career-changer who recently transitioned from teaching to wellness coaching. She has lived with PCOS for 25 years. Her primary physician told her she was "fine" because her LDL cholesterol was 112 mg/dL.</p>
 <p><strong>The Deep Dive:</strong> Elena's specialist ordered an advanced lipid panel. Despite the "normal" LDL, her <span class="highlight">ApoB was in the 85th percentile</span>, and her Triglyceride/HDL ratio was 4.2. She also presented with an elevated hs-CRP of 3.8 mg/L.</p>
 <p><strong>Outcome:</strong> By applying <strong>Therapeutic Glucose Tuning (Module 2)</strong> and targeted antioxidant support, Elena reduced her TG/HDL ratio to 1.8 and her hs-CRP to 0.9 within six months, significantly lowering her 10-year ASCVD risk score.</p>
 </div>
 </div>

 <h2 id="atherogenic-profile">1. The Atherogenic Lipoprotein Profile</h2>
 <p>In the PCOS population, the cardiovascular threat isn't necessarily <em>too much</em> cholesterol, but rather the <em>type</em> and <em>distribution</em> of the particles carrying it. This is known as the <span class="highlight">Atherogenic Lipoprotein Profile (ALP)</span>.</p>
 
 <p>The ALP is characterized by three primary deviations:</p>
 <ul>
 <li><strong>Hypertriglyceridemia:</strong> Elevated fasting triglycerides, often driven by hepatic overproduction of VLDL in response to insulin resistance.</li>
 <li><strong>Low HDL-C:</strong> Not just a lack of "good" cholesterol, but often a functional impairment of the HDL particles themselves.</li>
 <li><strong>Small Dense LDL (sdLDL):</strong> While the total LDL-C may be normal, the particles are small, dense, and highly susceptible to oxidation and penetration into the arterial wall.</li>
 </ul>

 <table class="data-table">
 <thead>
 <tr>
 <th>Marker</th>
 <th>Standard "Normal"</th>
 <th>Optimal for PCOS Specialist</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Triglycerides</td>
 <td>&lt; 150 mg/dL</td>
 <td>&lt; 100 mg/dL</td>
 </tr>
 <tr>
 <td>HDL-C</td>
 <td>&gt; 50 mg/dL</td>
 <td>&gt; 60 mg/dL</td>
 </tr>
 <tr>
 <td>TG/HDL Ratio</td>
 <td>N/A</td>
 <td>&lt; 2.0 (Ideally &lt; 1.5)</td>
 </tr>
 <tr>
 <td>LDL Particle Size</td>
 <td>Not Measured</td>
 <td>Pattern A (Large/Buoyant)</td>
 </tr>
 </tbody>
 </table>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The Ratio Secret</span>
 <p>üí° If you can only access a standard lipid panel, calculate the <strong>Triglyceride to HDL ratio</strong>. A ratio > 2.0 is a highly sensitive proxy for insulin resistance and the presence of small dense LDL particles. This is a powerful "aha" moment for clients whose doctors told them their "cholesterol is fine."</p>
 </div>

 <h2 id="insulin-axis">2. The Insulin-Endothelium Axis</h2>
 <p>Hyperinsulinemia does not just disrupt ovulation; it acts as a direct toxin to the <span class="highlight">endothelium</span>‚Äîthe single-cell thick lining of the blood vessels. In a healthy state, the endothelium produces <strong>Nitric Oxide (NO)</strong>, which allows vessels to dilate and maintain flexibility.</p>
 
 <p>In PCOS, chronic hyperinsulinemia and hyperandrogenism create a "perfect storm" for vascular damage:</p>
 <ol>
 <li><strong>Reduced NO Bioavailability:</strong> Insulin resistance in the endothelial cells impairs the PI3K pathway, leading to decreased Nitric Oxide production.</li>
 <li><strong>Increased Endothelin-1:</strong> The compensatory MAPK pathway remains active, increasing the production of Endothelin-1, a potent vasoconstrictor.</li>
 <li><strong>Oxidative Stress:</strong> Excess androgens and glucose spikes generate Reactive Oxygen Species (ROS), which "quench" remaining Nitric Oxide, leading to <span class="highlight">arterial stiffness</span>.</li>
 </ol>
 
 <p>A 2022 meta-analysis found that women with PCOS have significantly higher <strong>Pulse Wave Velocity (PWV)</strong>‚Äîa gold-standard measure of arterial stiffness‚Äîcompared to age-matched controls, even when BMI is accounted for.</p>

 <h2 id="advanced-markers">3. Beyond LDL: Advanced Biomarkers</h2>
 <p>To truly assess risk, we must look at markers that quantify the actual "cargo ships" (lipoproteins) and the "fire" (inflammation) in the system.</p>

 <h3>Apolipoprotein B (ApoB)</h3>
 <p>ApoB is the primary structural protein found on all potentially atherogenic particles (LDL, VLDL, IDL). Unlike LDL-C, which measures the <em>weight</em> of the cholesterol, ApoB measures the <em>number</em> of particles. <span class="highlight">Particle number is a superior predictor of risk</span> because it is the number of particles that determines how many will get trapped in the arterial wall.</p>

 <h3>Lipoprotein(a) [Lp(a)]</h3>
 <p>Lp(a) is a genetically determined variant of LDL that is highly pro-thrombotic (prone to clotting) and pro-atherogenic. It is not affected by diet or exercise. Every woman with PCOS should have this tested <strong>once in her lifetime</strong> to establish her genetic baseline risk.</p>

 <h3>High-Sensitivity C-Reactive Protein (hs-CRP)</h3>
 <p>This is a marker of systemic "low-grade" inflammation. In PCOS, hs-CRP is frequently elevated (often between 1.0 and 3.0 mg/L), signaling that the immune system is primed for vascular injury. Reducing this marker is a primary goal of <strong>Detoxification & Inflammation Control (Module 5)</strong>.</p>

 <div class="coach-tip">
 <span class="tip-label">Practitioner Income Insight</span>
 <p>üí° Specialists who offer "Advanced Metabolic Mapping"‚Äîwhich includes interpreting these markers‚Äîoften command fees of <strong>$350-$500 per consultation</strong>. By providing clarity where conventional medicine provides "normal" ranges, you position yourself as an essential high-value partner in your client's longevity.</p>
 </div>

 <h2 id="screening-protocols">4. Long-term Screening Protocols</h2>
 <p>Cardiovascular health management in PCOS requires a proactive, multi-modal screening approach. We cannot wait for a "cardiac event" to intervene.</p>
 
 <ul>
 <li><strong>Ambulatory Blood Pressure Monitoring:</strong> Women with PCOS often exhibit "masked hypertension" or a lack of "nocturnal dipping" (where BP fails to drop at night). Home monitoring is essential.</li>
 <li><strong>Carotid Intima-Media Thickness (CIMT):</strong> This ultrasound test measures the thickness of the inner layers of the carotid artery. It can detect subclinical plaque long before a stress test or standard imaging would show a blockage.</li>
 <li><strong>Coronary Artery Calcium (CAC) Score:</strong> Recommended for women over 45 or those with significant risk factors to quantify existing calcified plaque.</li>
 </ul>

 <h2 id="interventions">5. Therapeutic Interventions for Cardioprotection</h2>
 <p>Our goal is to move the client from a "pro-inflammatory" state to a "vasculo-protective" state using the S.T.E.A.D.Y. Method‚Ñ¢.</p>

 <div class="nutrient-box positive">
 <h3>The Cardioprotective PCOS Protocol</h3>
 <div class="nutrient-grid">
 <div class="nutrient-item">
 <h4>Macro-Buffer Strategy</h4>
 <p>Prioritizing 30g+ of fiber daily to bind bile acids and lower ApoB naturally.</p>
 </div>
 <div class="nutrient-item">
 <h4>Omega-3 Optimization</h4>
 <p>Targeting an Omega-3 Index > 8% to reduce TG and dampen systemic inflammation.</p>
 </div>
 <div class="nutrient-item">
 <h4>Magnesium & Potassium</h4>
 <p>Essential for endothelial relaxation and blood pressure regulation.</p>
 </div>
 <div class="nutrient-item">
 <h4>Zone 2 Training</h4>
 <p>Low-intensity steady-state exercise to improve mitochondrial flexibility and NO production.</p>
 </div>
 </div>
 </div>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Explaining Small Dense LDL</span>
 <p>üí° Use the "Golf Ball vs. Beach Ball" analogy. Large, fluffy LDL (Pattern A) are like beach balls‚Äîthey bounce off the arterial walls. Small dense LDL (Pattern B) are like golf balls‚Äîthey are heavy, fast, and easily get stuck in the "grass" (the endothelial lining), where they cause damage.</p>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 <div class="question-item">
 <p class="question-text"><strong>1. Why is a "normal" LDL-C often misleading in a woman with PCOS?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">LDL-C measures the weight of cholesterol, not the particle count. Women with PCOS often have many small, dense LDL particles (high particle count) that are more atherogenic, even if the total weight (LDL-C) appears normal.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. What is the clinical significance of a TG/HDL ratio greater than 2.0?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">A ratio > 2.0 is a strong indicator of insulin resistance and a proxy for the presence of small dense LDL particles, which are highly prone to oxidation and arterial damage.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. How does hyperinsulinemia directly affect blood vessel flexibility?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">It impairs the production of Nitric Oxide (a vasodilator) and increases the production of Endothelin-1 (a vasoconstrictor), leading to endothelial dysfunction and increased arterial stiffness.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. Which marker should be tested once in a lifetime to assess genetic cardiovascular risk?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">Lipoprotein(a) or Lp(a). It is genetically determined and provides a baseline for a client's inherent risk for clotting and plaque formation.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>Look Beyond LDL:</strong> Standard lipid panels miss the atherogenic lipoprotein profile (ALP) common in PCOS.</li>
 <li><strong>Prioritize ApoB:</strong> ApoB is a more accurate measure of cardiovascular risk than LDL-C as it counts the actual number of atherogenic particles.</li>
 <li><strong>The Insulin Connection:</strong> Cardiovascular disease in PCOS is driven by the insulin-androgen axis, not just dietary fat intake.</li>
 <li><strong>Screen Early:</strong> Subclinical atherosclerosis can begin in the 20s and 30s for women with PCOS; early screening with TG/HDL ratios and hs-CRP is vital.</li>
 <li><strong>Lifestyle is Primary:</strong> Therapeutic glucose tuning and fiber-rich nutrition are the most effective tools for shifting LDL patterns from dense to buoyant.</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Osibogun, O. et al. (2020). "Polycystic Ovary Syndrome and Cardiometabolic Risk: A Systematic Review." <em>Journal of Clinical Endocrinology & Metabolism.</em></li>
 <li>Dabadghao, P. et al. (2022). "Endothelial Dysfunction and Arterial Stiffness in Women with PCOS." <em>Fertility and Sterility.</em></li>
 <li>Sniderman, A. D. et al. (2021). "Apolipoprotein B vs LDL-C: The Case for a New Standard of Care." <em>JAMA Cardiology.</em></li>
 <li>Wild, R. A. et al. (2019). "Long-term Cardiovascular Risk in Women with PCOS: A Meta-Analysis." <em>Clinical Endocrinology.</em></li>
 <li>Glintborg, D. et al. (2021). "Cardiovascular risk in PCOS: A review of the role of androgens and insulin resistance." <em>Endocrine Connections.</em></li>
 <li>Androulakis, N. et al. (2020). "Small Dense LDL Particles in Polycystic Ovary Syndrome: The Role of Insulin Resistance." <em>Metabolism.</em></li>
 </ol>
 </div>
</div>

<script>
 document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 const isVisible = answer.style.display === 'block';
 answer.style.display = isVisible ? 'none' : 'block';
 this.textContent = isVisible ? 'Reveal Answer' : 'Hide Answer';
 }
 });
 });
</script>

</body>
</html>